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Introduction
The introduction of rapid laboratory testing for crea-
tine kinase (CK)-MB greatly revolutionized the diag-
nosis and management of acute myocardial infarction
(AMI) in the 1970s and 1980s.1,2 Conditions that are
known to lower the sensitivity and specificity of CK-
MB activity assays include false-positive results in renal
failure patients, concurrent skeletal muscle and myo-
cardial injuries, and many other conditions, such as
non-cardiac surgery, chest trauma, asthma, malignan-
cies and pulmonary embolism.1–3 Among the condi-
tions in which CK-MB activity is elevated in the absence
of myocardial injury, the presence of macroenzyme
(macro) CK merits special attention from clinicians.
Macro CK is one of the most common macroenzymes,
which are enzymes with a higher molecular mass than
the corresponding enzymes that are normally found
in serum.4–7 Macro CK occurs in 2 major forms.
Macro CK type 1 is an enzyme-antibody complex
with a molecular weight greater than 200 kDa, and is
formed by 1 of the CK isoenzymes (most often, CK-
BB) and immunoglobulin (most often, IgG with a
kappa light chain; occasionally IgA; and rarely, IgM).8
In contrast to macro CK type 1, macro CK type 2 is a
non-immunoglobulin-bound macroenzyme produced
by a separate gene.9 Macro CK type 2 is a polymer of
mitochondrial CK with a molecular mass greater than
300 kDa.6,10 Both macro CK types 1 and 2 are well
known to cause falsely elevated CK-MB activity, which
often leads to diagnostic confusion and unnecessary
investigation for myocardial injury. The detection of
macro CK requires careful laboratory interpretation,
and sometimes additional biochemical tests are needed
to establish the proper diagnosis.
In this report, we present 2 individual cases, 1 with
macro CK type 1 and the other with macro CK type 2.
In the case involving macro CK type 1, the impor-
tance of the differential diagnosis with a true AMI in a
patient who presents symptoms mimicking acute coro-
nary syndrome (ACS) is highlighted. In the case involv-
ing macro CK type 2, we stress both the common
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scenario and an unusually high CK-MB activity in
association with the presence of macro CK type 2 in a
cancer patient. The biochemical characteristics, clini-
cal significance, and potential implications of macro
CK are reviewed within the scope of modern labora-
tory medicine.
Case Reports
Case 1
A 72-year-old Taiwanese female suffered from inter-
mittent chest tightness, and had undergone a serial
work-up for AMI, including serial measurement of CK
and CK-MB activities, troponin I levels and percuta-
neous coronary intervention, all of which revealed neg-
ative findings. The physical examination on admission
revealed no remarkable findings. The patient had a
history of asymptomatic chronic hepatitis C, without
cryoglobulinemia. The blood biochemistry tests were
normal, except for mildly elevated liver enzymes (ala-
nine aminotransferase, 57 U/L; aspartate aminotrans-
ferase, 62 U/L) and increased total CK (311 U/L) and
CK-MB (108 U/L). In addition, a serum CK isoen-
zyme electrophoresis was performed using an auto-
mated electrophoresis apparatus (Epalyzer-II; Helena
Laboratories Inc., Saitama, Japan), which revealed the
presence of macro CK type 1 with a percentage of
12.8% (35 U/L) (Figure 1). In the following 2 years
of follow-up, the cardiac biochemistry profile showed
persistent mildly elevated CK with the presence of
macro CK type 1.
Case 2
A 41-year-old Taiwanese female sought evaluation at
our hospital for the acute onset of chest tightness and
dyspnea. The physical examination revealed a mildly
engorged jugular vein with clear breath sounds and
no evidence of a cardiac murmur; however, a palpable
mass measuring 4 × 1 cm was present over the left
breast. The electrocardiograms and chest roentgeno-
grams were normal. Biochemical testing of the blood
showed an elevated total CK (359 U/L), with an ab-
normal CK-MB (1,367U/L) by a CK-MB monoclonal
antibody immunoinhibitory assay (Kanto Chemical
Co., Inc., Tokyo, Japan), and an undetectable troponin
I value. Chest computed tomography (CT) with con-
trast enhancement confirmed the palpable mass over
the medial upper quadrant of the left breast. Chest
CT also showed another metastatic nodule (1.5 cm in
diameter) at the medial upper quadrant of the right
breast, multiple osteolytic metastatic bony lesions
involving the thoracic and lumbar spine, and multiple
tiny pulmonary metastatic nodules within the lung
fields bilaterally. After admission, an echocardiogram
confirmed the presence of severe pulmonary hyper-
tension with a measured pulmonary artery systolic
pressure of 98 mmHg. Repeat serum biochemical
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Figure 1. Electrophoresis results of serum creatine kinase (CK)
isoenzymes of Case 1. (A) The peak patterns of electrophoresis
by densitometry and the fractions of CK isoenzymes were ana-
lyzed automatically. (B) Agarose gel electrophoresis shows a pos-
itive band (arrow) migrating anodal to the CK-MM band, between
the CK-MB and CK-MM bands, indicative of macro CK type 1.
Macro-1 = macro CK type 1; BB = CK isoenzyme CK-BB; MB = CK
isoenzyme CK-MB; MM = CK isoenzyme CK-MM; M = markers;
P1 = patient (Case 1); N = normal control; A = acute myocardial
infarction patient with elevated CK-MB.
tests showed persistently elevated total CK levels and
abnormally high CK-MB activity levels. A CK isoen-
zyme electrophoresis (Epalyzer-II; Helena Laborato-
ries Inc.) confirmed the presence of macro CK type 2
with a percentage of 63.3% (342 U/L), with a total
CK of 540 U/L, and a CK-MM of 198 U/L (36.7%)
(Figure 2). The patient also had positive signs of dis-
seminated intravascular coagulopathy associated with
an underlying malignancy. A pathologic diagnosis of
stage IV invasive ductal carcinoma of the left breast
was made based on the tissue biopsy.
Discussion
Elevated CK and CK-MB activity often leads to a 
suspicion of AMI or ACS, especially when patients
present with chest symptoms mimicking angina pec-
toris, and the presence of macro CK can be trouble-
some. Although currently, the diagnostic confusion
of AMI/ACS with macro CK can be resolved by care-
ful identification of macro CK (by measuring the 
CK-MB mass assay which directly determines the
antigenic amount of CK-MB, or by the determina-
tion of troponin levels1,11,12), in areas where CK-MB
mass or troponin assays are not available, CK and 
CK-MB activity assays are still reliable, and the identi-
fication of macro CK avoids unnecessary and costly
diagnostic procedures. Macro CK can usually be recog-
nized on CK electrophoresis. Occasionally, other tests
may be needed to unmask a macro CK co-migrating
with CK-MM or CK-MB, such as the combined use
of immunoprecipitation and electrophoresis,13,14 the
heat stability method,15 or energy kinetics characteri-
zation.16 Often, macro CK causes only a mild ele-
vation (< 500 IU/L) in CK or a high CK-MB/CK
ratio with a normal level of total CK.17 Clinically, the
absence of symptoms, the presence of symptoms
atypical for the abnormal level of CK, or an isolated
and persistently increased CK favor the presence of
macro CK.6,7,17
CK-MB activity by immunoinhibition assay is based
on the inhibition of all M subunits by anti-M anti-
body, allowing determination of residual B subunit
enzyme activity by anti-B antibody. Both macro CK
types 1 and 2 can cause a falsely elevated CK-MB ac-
tivity. Increased amount of CK-BB-immunoglobulin
complex (macro CK type 1) is resistant to inhibition
by the anti-M antibody. On the other hand, macro
CK type 2 is not structurally related to the M or B
subunits, nor is it inhibited by monoclonal anti-M
antibody. In our 2nd case, the measured CK-MB activ-
ity was nearly 3 times more than that of the estimated
macro CK type 2 by electrophoresis and vastly ex-
ceeded the total CK level, showing that macro CK
type 2 abnormally reacted with the anti-B antibody
during the immunoinhibition assay. Rarely, under cer-
tain pathological conditions, abnormally increased
CK-BB may contribute to the falsely elevated CK-MB
activity that may exceed total CK activity. Jap et al18
reported a patient with rectal adenocarcinoma and an
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Figure 2. Electrophoresis results of serum creatine kinase (CK)
isoenzymes of Case 2. (A) The peak patterns of electrophoresis
by densitometry and the fractions of CK isoenzymes were analyzed
automatically. (B) Agarose gel electrophoresis shows a positive
band (arrow) migrating cathodal to the CK-MM band, indicative of
macro CK type 2. Macro 2 = macro CK type 2; BB = CK isoenzyme
CK-BB; MB = CK isoenzyme CK-MB; MM = CK isoenzyme CK-MM;
M = markers; N = normal control; P2 = patient (Case 2).
extremely high CK-MB activity greater than the total
CK level, in which the etiology was attributed to 
a marked elevated immunoglobulin-bound CK-BB
complex (macro CK type 1) that was caused by the
rectal cancer.
The prevalence of macro CK type 1 has been re-
ported to range from 0.54% to 2.3%.5 The clinical sig-
nificance of macro CK type 1 remains of interest to
clinicians, and there is no well-established association
of a particular disease with macro CK type 1. Never-
theless, it has been reported to be associated with a
variety of diseases, including hypothyroidism, malignan-
cies, autoimmune diseases, myositis, and cardiovascu-
lar disease.8,17,19,20 More rarely, macro CK 1 has been
described in patients with irritable bowel syndrome,
bronchopulmonary chronic illness,8 or in association
with other macroenzymes, such as macroamylasemia21
and macro-lactate dehydrogenase.22 Case 1 had no
hepatitis C-associated cryoglobulinemia that might
potentially explain the formation of immune com-
plex. It remains unclear whether macro CK type 1 is
associated with the hepatitis C carrier state.
Macro CK type 2 is detected in up to 3.7% of hos-
pitalized patients.23 It is frequently found in patients
who are critically ill or who have widespread tissue
damage, such as severe liver disease and disseminated
malignancies.6,8,10,23,24 In general, the presence of
macro CK type 2 may be viewed as a warning signal
of occult malignancies, a poor prognostic sign in pa-
tients with a malignancy, or a reflection of the severity
of an underlying illness.4–6,8,25
In conclusion, macro CK can occur as an inciden-
tal finding in healthy individuals or as a marker of cer-
tain diseases (autoimmune diseases, cancer, severe
liver disease, and serious illness). It is particularly
important to recognize macro CK in patients with
symptoms mimicking ACS, to avoid unnecessary spe-
cialist consultations and invasive procedures. Despite
the usefulness of troponin assays, confirmation is re-
quired to completely replace CK and CK isoenzymes
by troponins in AMI/ACS diagnosis. It is important
for clinicians to understand the biochemistry and
clinical significance of macro CK in the context of
modern laboratory medicine.
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